Document:

Exhibit 10.05

 

AMENDMENT NUMBER ONE

 

TO THE

 

AMYRIS, INC. 2010 EMPLOYEE STOCK PURCHASE
PLAN

 

WHEREAS, Amyris,
Inc., a Delaware corporation (the “Company”), maintains the Amyris, Inc. 2010 Employee Stock Purchase
Plan, effective as of September 27, 2010 (the “Plan”; capitalized terms used but not defined herein shall
have the meanings given to such terms in the Plan);

 

WHEREAS, pursuant
to Section 25 of the Plan, the Leadership Development and Compensation Committee of the Board of Directors of the Company (the
“Committee”) has the authority to amend the Plan, subject to stockholder approval of any Plan amendment
to (i) increase the number of shares that may be issued under the Plan or (ii) change the designation of the employees (or class
of employees) eligible for participation in the Plan, and subject to the limitations of Section 423 of the Internal Revenue
Code of 1986, as amended; and

 

WHEREAS, the
Committee has authorized an amendment of the Plan (this “Amendment”) to increase the maximum number of
shares which may be purchased by any Participant during any one Offering Period under the Plan.

 

NOW, THEREFORE,
BE IT RESOLVED, that the Plan is hereby amended, effective as of February 15, 2017, as follows:

 

Section 10(b) of
the Plan is hereby amended and restated as follows:

 

“(b)  The Committee
may, in its sole discretion, set a lower maximum number of shares which may be purchased by any Participant during any Offering
Period than that determined under Section 10(a) above, which shall then be the Maximum Share Amount for subsequent Offering
Periods; provided, however, in no event shall a Participant be permitted to purchase more than 8,000 Shares during any one Offering
Period, irrespective of the Maximum Share Amount set forth in (a) and (b) hereof. If a new Maximum Share Amount is set,
then all Participants must be notified of such Maximum Share Amount prior to the commencement of the next Offering Period for which
it is to be effective. The Maximum Share Amount shall continue to apply with respect to all succeeding Offering Periods unless
revised by the Committee as set forth above.”

***

 

IN WITNESS WHEREOF, the Company
has caused this Amendment to be executed by its duly authorized officer as of February 16, 2017.

 

 

	 	 	AMYRIS, INC.
	 	 	 
	 	 	By: 	/s/ John Melo
	 	 	Name: 	John Melo
	 	 	Title:	President and Chief Executive OfficerExhibit 10.06

 

Execution Version

 

 

 

AMENDMENT #2 TO THE SECOND AMENDMENT

TO THE TECHNOLOGY, LICENSE, DEVELOPMENT, RESEARCH AND COLLABORATION
AGREEMENT

 

 

This Amendment #2 to the Second Amendment to the Technology, License,
Development, Research and Collaboration Agreement (the “Amendment #2”) is entered into to be effective as of
February 28, 2017 (the “Amendment #2 Effective Date”), by and between Amyris, Inc., a Delaware corporation having
its place of business at 5885 Hollis Street, Suite 100, Emeryville, California 94608 (“AMYRIS”) and Total Energies
Nouvelles Activités USA SAS (formerly known as Total Gas & Power USA SAS), a company existing and organized under the
French law having its head office located at 24, cours Michelet, 92800 Puteaux, France (“TOTAL”). AMYRIS and
TOTAL are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.

 

RECITALS

 

WHEREAS, on June 21, 2010, AMYRIS and TOTAL Gas & Power USA
Biotech, Inc. entered into the Technology License, Development, Research and Collaboration Agreement, as amended by the First Amendment
dated as of November 23, 2011 (the “Agreement”);

 

WHEREAS, TOTAL Gas & Power USA Biotech, Inc. assigned the Agreement
to TOTAL as set forth in that certain letter dated January 11, 2011;

 

WHEREAS, on July 30, 2012, TOTAL and AMYRIS amended certain portions
of the Agreement by entering into the Second Amendment to the Technology, License, Development, Research and Collaboration Agreement
(as subsequently amended by the Amendment #1 to the Second Amendment to the Technology, License, Development, Research and Collaboration
Agreement on April 1, 2015, collectively, the “Second Amendment”);

 

WHEREAS the Parties now desire to further amend a provision in the
Second Amendment; and

 

NOW THEREFORE, for good and valuable consideration the receipt of
which is hereby acknowledged, the Parties, intending to be legally bound, agree to the following provisions and to amend the Second
Amendment, as follows:

 

1.     
Defined Terms. All capitalized terms used, but not defined, in this Amendment #2 have the same meaning as in the
Agreement.

 

2.     
Amend Section 3.B to Extend the Term. Pursuant to Section 13.2 of the Agreement, the Parties hereby delete Section
3.B of the Second Amendment in its entirety and replace it with the following new Section 3.B:

 

“B. Term. Unless otherwise extended by the
Parties via a signed written agreement, the Biofene Development Project shall continue until the earliest to occur of (i) the Parties
terminate the Biofene Development Project by mutual written agreement signed by the Parties; or (ii) December 31, 2017.”

 

3.       No
Other Changes. Except as specifically modified herein, all other terms of the Second Amendment and the Agreement shall remain
in full force and effect.

This Amendment #2 is executed by the authorized representatives of the Parties as of
the Amendment #2 Effective Date,

 

    	 	1 of 2	 

     

    

Execution Version

 

	AMYRIS, INC.	 	TOTAL ENERGIES NOUVELLES ACTIVITES USA, SAS
	 	 	 	 	 	 
	 	/s/ John Melo	 	 	/s/ Christophe Vuillez	 
	 	 	 	 	 	 
	Name	John Melo	Name	Christophe Vuillez	 
	 	 	 	 	 	 
	Title:	President & CEO	 	Title:	Attorney in Fact	 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2 of 2CONFIDENTIAL
TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS DOCUMENT HAVE BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND,
WHERE APPLICABLE, HAVE BEEN MARKED WITH AN ASTERISK TO DENOTE WHERE OMISSIONS HAVE BEEN MADE. THE CONFIDENTIAL MATERIAL HAS BEEN
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

 

 

 

Exhibit 10.07

 

Total Energies Nouvelles Activités USA
SAS

24 Cours Michelet

92800 Puteaux

France

 

February 28, 2017

 

Amyris, Inc.

5885 Hollis Street, Suite 100

Emeryville, California 94608

USA

Attention: Mr. John Melo, President & CEO

 

Total New Energies, Inc.

1201 Louisiana Street, Suite 1600

Houston, Texas 77002

USA

Attention: Mrs Isabelle Kieffer, CEO

 

Total Amyris BioSolutions B.V.

Hoogoorddreef 15

1101 BA Amsterdam

Netherlands

Attention: Mr Philippe Marchand, General Manager

 

 

SIDE LETTER

 

Reference is made to (i) that certain
Technology License, Development, Research and Collaboration Agreement between Amyris, Inc. (“Amyris”) and
Total New Energies Inc. (“TNE”, formerly known as Total Gas & Power USA Biotech, Inc.), dated as of
June 21, 2010 (as such agreement may be amended from time to time by the parties thereto, including by that certain Amendment
# 2 to the Second Amendment to the Collaboration Agreement, effective as of February 28, 2017, the “Collaboration
Agreement”), which Collaboration Agreement was assigned by TNE by letter agreement dated January 11, 2011 to Total
Energies Nouvelles Activités USA SAS (“TENA”, formerly known as Total Gas & Power USA SAS);
(ii) that certain Amended and Restated Secondment Agreement between TNE and Amyris, dated August 1, 2012 (as such agreement
may be amended from time to time by the parties thereto, including by that certain Amendment #1 to the Secondment Agreement,
effective as of May 1, 2016, the “Secondment Agreement”); (iii) that certain License Agreement between
Amyris and Total Amyris BioSolutions B.V. (the “Company”), dated December 2, 2013, which was amended and
restated on March 21, 2016 (as such agreement may be amended from time to time by the parties thereto, including by that
certain First Amendment to the Amended and Restated Jet Fuel License Agreement, effective as of February 14, 2017, the
“Amended and Restated Jet Fuel License Agreement”); and (iv) that certain License Agreement regarding
Diesel Fuel in the EU between Amyris and TENA, dated March 21, 2016 (as such agreement may be amended from time to time by
the parties thereto, including by that certain First Amendment to License Agreement regarding Diesel Fuel in the EU,
effective as of February 14, 2017, the “Diesel Fuel License Agreement”, and together with the
Collaboration Agreement, the Secondment Agreement and the Amended and Restated Jet Fuel License Agreement, collectively, the
“Agreements”).

 

    	1

     

    

 

In addition to the rights and obligations of
the parties hereto provided in the Agreements, we are writing to you to confirm our mutual agreement on the issues set out below.

 

		1.	Definitions.

 

Capitalized terms used herein but not otherwise
defined shall have the meaning set forth in the applicable Agreement.

 

		2.	Extension of Biofene Development Project.

 

		a.	On July 29, 2016 the Management Committee decided to extend the term of the Biofene Development
Project from July 31, 2016 to March 1, 2017. TENA and Amyris have further extended the term of the Biofene Development Project
until December 31, 2017, as per that certain Amendment # 2 to the Second Amendment to the Collaboration Agreement, effective as
of February 28, 2017 (“Amendment #2”).

 

		b.	The parties hereto agree that each of (i) the Management Committee’s decision on July 29,
2016 to extend the term of the Biofene Development Program to March 1, 2017, and (ii) Amendment #2, is a Biofene Development Project
Extension Agreement, as such term is used in each of the Diesel Fuel License Agreement and the Jet Fuel License Agreement.

 

		c.	For purposes of clarification, the expiration of the Biofene Development Project Extension Agreement
shall automatically occur on the date that Biofene Development Project terminates as per Amendment #2.

 

		3.	Outstanding Amount Owed by Amyris for Seconded Employees as of May 1, 2016.

 

		a.	The parties hereto agree that the aggregate unpaid Amyris Share owed by Amyris as per the Secondment
Agreement, equals [*]. However, TNE agrees that Amyris may deduct from such outstanding amount the sum of [*]

 

 

[*] Certain portions denoted with an asterisk
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

 

    	2

     

    

 

[*] as
and for satisfaction of the rent payment obligation of TENA through December 31, 2017, under the Sublease between the Amyris and
TENA, dated April 4, 2014. As a result of such deduction, the parties hereto agree that Amyris’ outstanding balance for the
Amyris Share is [*] (the “Agreed Upon Secondee Payable”). 

 

		b.	The Agreed Upon Secondee Payable will be paid by Amyris to TNE on or before June 30, 2017. Such
payment shall satisfy all Amyris payment obligations related to Amyris Share, and claims related to any past-due payment thereof.

 

		4.	Biofene Development Project Milestones.

 

Amyris and TENA agree that the 2017 quarterly
technical milestones of the Biofene Development Project are described in Appendix A, attached hereto and incorporated herein by
reference.

 

		5.	Biofene Development Project Expenses.

 

Each of Amyris and TENA agrees to track (i)
the hours that its employees (including, in the case of TENA, its Seconded Employees at the Amyris Facilities) spend working on
the Biofene Development Project after April 30, 2016 and (ii) the expenses incurred for third-party services and/or equipment for
the Biofene Development Project after April 30, 2016.

 

		6.	Out-of-Scope Expenses.

 

On the request of either Amyris or TENA, the
other party shall consider on a case-by-case basis whether to share the cost of third-party expenses incurred outside the scope
of the Biofene Development Project. Any agreement reached between Amyris and TENA in this respect must be evidenced in writing
and signed by both parties.

 

		7.	Miscellaneous.

 

		a.	This Side Letter and any arbitration hereunder shall be governed by, interpreted and construed
and enforced in accordance with, the laws of the State of New York, without giving effect to any conflicts of laws principles thereof.
Each party irrevocably consents and agrees that any action for relief brought against it with respect to its obligations or liabilities
under or arising out of or in connection with this Side Letter may be brought in the United States District Court for the Southern
District of New York, unless no federal subject matter jurisdiction exists, in which case the action may be brought
in the courts of the State of new York located in the Borough of Manhattan, and each party herby irrevocably accept and unconditionally
submits to the non-exclusive jurisdiction of aforesaid courts in personam, with respect to any action for relieve. The language
of any proceedings and of all submissions and written evidence shall be English; provided, however, that a party, at its expense,
may provide for translation or simultaneous interpretation into a language other than English.

 

 

*] Certain portions denoted with an asterisk
have been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with
respect to the omitted portions.

 

    	3

     

    

 

		b.	Neither this Side Letter nor any right or obligations hereunder may be assigned or delegated by
any of the parties hereto without the written consent of the other parties hereto, except that TENA may assign the Side Letter
and its rights and obligations hereunder to its affiliate Total Raffinage Chimie, S.A., by giving written notice of such assignment
to Amyris.

 

		c.	This Side Letter may be executed in multiple counterparts, each of which will be deemed to be an
original and all of which will be deemed to be a single document.

 

 

 

Very truly yours,

 

Total Energies Nouvelles Activités USA SAS

 

 

	By: 	/s/ Christophe Vuillez	 	 
	Name:   	Christophe Vuillez	 	 
	Title:	Attorney in Fact	 	 
	 	 	 

 

 

 

 

 

 

 

    	4

     

    

 

Agreed and accepted by:

 

	Amyris, Inc.	 	 
	By:	/s/ John Melo	 	 
	Name     	John Melo	 	 
	Title:	President & CEO	 	 
	 	 	 	 
	Total New Energies, Inc.	 	 
	By:	/s/ Isabelle Kieffer	 	 
	Name	Isabelle Kieffer	 	 
	Title:	Chief Executive Officer	 	 
	 	 	 	 
	Total Amyris BioSolutions B. V.	 	 
	By:	/s/ Xavier de Maupeou	 	 
	Name	Jean-Marc Otereo del
    Val Xavier de Maupeou	 	 
	Title:	General Manager	 	 
	 	 	 	 
	By:	/s/ Remi Bourgeois	 	 
	Name	Remi Bourgeois	 	 
	Title:	General Manager	 	 
	 	 	 	 
	By:	/s/ Philippe Marchand	 	 
	Name	Philippe Marchand	 	 
	Title:	General Manager	 	 

 

 

 

 

    	5

     

    

 

Exhibit A

 

2017 quarterly technical milestones for the Biofene Program

 

 

	 	
        YE 2016

        ActualA
	
        2017 Q1

        GoalA
	
        2017 Q2

        GoalA
	
        2017 Q3

        GoalA
	
        2017 Q4

        GoalB

	Fermentation yield (wt. %)	[*]	[*]	[*]	[*]	[*]
	Productivity (g/L/h)	[*]	[*]	[*]	[*]	[*]
	Recovery yield (wt. %)C	[*]	[*]	[*]	[*]	[*]

 

A Fermentation
yield and productivity to be measured at [*]

B Fermentation
yield and productivity to be measured at [*]

C Recovery yield
to be monitored at [*]

 

 

 

 

 

 

 

 

 

 

 

 

[*] Certain portions denoted with an asterisk have been omitted and
filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

A-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00271-of-00352.parquet"}]]